Zitat von DomRuinart: Mein Reden...

Puma Biotechnology: Increasing Our Exposure
Dec. 10, 2018 6:43 AM ET

Summary:
Puma Biotechnology announced positive results for a number of Nerlynx ongoing trials.

It is possible that Kadcyla's KATHERINE results negatively affected Puma's stock, but we think that Kadcyla and Nerlynx have different labels.

We sold our Tesaro position and increased our exposure to Puma, as we think that Puma may be a good acquisition target.

Thesis:
We sold our position in Tesaro (TSRO) and are increasing our exposure to Puma Biotechnology (PBYI) as we think that Puma can be a good acquisition target as a small-cap, $250 million sales, oncology company with promising growth prospects.

Puma is expected to become cash flow positive/neutral in Q4 2018 and is expected to launch Nerlynx in Europe during 2019.

Puma's stock is still traded at multi-year lows due to concerns associated with Kadcyla's new indications as well as Nerlynx' high discontinuation rates.

Quelle: Seeking Alpha